Published June 13, 2022
| Version 1.0.0
Dataset
Open
Risk of bias assessments and support for judgement with ROB 2 tool for the Cochrane Review: Janus kinase inhibitors for the treatment of COVID-19
Authors/Creators
- Kramer,. Andre1
- Prinz, Carolin2
- Fichtner, Falk1
- Fischer, Anna-Lena1
- Thieme, Volker1
- Grundeis, Felicitas1
- Spagl, Manuel1
- Seeber, Christian1
- Piechotta, Vanessa3
- Metzendorf, Maria-Inti4
- Golinski, Martin2
- Moerer, Onnen2
- Stephani, Caspar2
- Mikolajewskaja, Agata5
- Kluge, Stefan6
- Stegemann, Miriam5
- Laudi, Sven1
- Skoetz, Nicole7
- 1. Department of Anaesthesiology and Intensive Care, University of Leipzig Medical Center, Leipzig, Germany
- 2. Department of Anesthesiology, University Medical Center Göttingen, Georg August University, Göttingen, Germany
- 3. Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- 4. Cochrane Metabolic and Endocrine Disorders Group, Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- 5. Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- 6. Department of Intensive Care Medicine, Medical Center Hamburg Eppendorf (UKE), Hamburg, Germany
- 7. Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Description
Risk of bias assessments and support for judgement with ROB 2 tool for the Cochrane Review: Janus kinase inhibitors for the treatment of COVID-19.
Notes
Files
Files
(452.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:2def1198d9924fb96060c7d5922d1d73
|
452.2 kB | Download |